Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.
E. Q. Wu
Consultant or Advisory Role - Analysis Group
J. Xie
Consultant or Advisory Role - Analysis Group
J. Signorovitch
Consultant or Advisory Role - Analysis Group
M. Diener
Consultant or Advisory Role - Analysis Group
R. Sorg
Consultant or Advisory Role - Analysis Group
M. Namjoshi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis